Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome
about
Oncogenic Intra-p53 Family Member Interactions in Human CancersMutant p53: One, No One, and One Hundred ThousandIdentifying new small molecule anti-invasive compounds for glioma treatmentThe rebel angel: mutant p53 as the driving oncogene in breast cancer.Gain of function of mutant p53: R282W on the peak?The microRNA feedback regulation of p63 in cancer progressionMathematical model of a telomerase transcriptional regulatory network developed by cell-based screening: analysis of inhibitor effects and telomerase expression mechanismsFunctional interplay between MDM2, p63/p73 and mutant p53More targets, more pathways and more clues for mutant p53.DNA damage induces expression of WWP1 to target ΔNp63α to degradationMiR-766 induces p53 accumulation and G2/M arrest by directly targeting MDM4.Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2.Identification of new p53 target microRNAs by bioinformatics and functional analysisTAp73 promotes anabolismp53 Represses the Oncogenic Sno-MiR-28 Derived from a SnoRNAA global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues.Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis.Global tumor protein p53/p63 interactome: making a case for cisplatin chemoresistance.p63 threonine phosphorylation signals the interaction with the WW domain of the E3 ligase ItchMutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).ΔNp63α represses anti-proliferative genes via H2A.Z deposition.Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase AxlTissue-specific expression of p73 C-terminal isoforms in mice.The "Sharp" blade against HIF-mediated metastasis.p63 the guardian of human reproduction.Answering the ultimate question "what is the proximal cause of aging?"Recent discoveries in the cycling, growing and aging of the p53 fieldRecent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.TAp63 regulates oncogenic miR-155 to mediate migration and tumour growth.The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.TP53 mutants in the tower of babel of cancer progression.The aggregation of mutant p53 produces prion-like properties in cancer.Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.Proteomic profiling of the cancer cell secretome: informing clinical research.Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking.Targeting mutant p53 in cancer: a long road to precision therapy.
P2860
Q26749382-3ACB4136-5181-4072-9540-98F43BAE4B2EQ26770576-18223C38-5CE0-4216-8987-975EC5547C3DQ27025151-0829F204-31F4-4AC3-B9C0-153413D7C23AQ27686765-47CFEB22-4B30-4664-8FFB-E4B5EE3E3B44Q28068551-61EFA3E2-24B4-4B1F-9BAB-8BEACA6A5F59Q28084646-B08F4AF3-447F-462C-B5C7-82235C0C3A07Q28539760-6E26EDFA-A684-4CFC-BC3A-888F9BB868EAQ28910323-013BE586-E6C8-43AA-B9C0-96537A44B07FQ30542607-7AFE8B27-14E1-4356-9916-3D2D9A7EA664Q33584994-61F108D7-FB80-49FE-A9B4-F2ABCA819ED8Q33728193-99EFFA44-398A-4FDB-AFC3-A39761005DBFQ34516626-7E136FEB-971B-4553-939D-40754AEA504EQ35047617-7C2F4B7B-B91F-4FD1-AAEC-A45C705F6936Q35149652-E23952C9-6A97-4B2D-A2C7-AC6B5B85D982Q35659515-FDCD131D-4D19-4A98-BBD0-9DF6B5629757Q35739462-1B0184FD-B49B-43C2-85B6-2E951BFD3779Q35987073-5A7C7CCA-35C5-4157-8ACD-75205A262407Q36059712-6D203BC7-F970-40F9-A4BD-099F057E8131Q36183728-D3EA00FE-938F-4DE8-9EFC-E68544636884Q36293880-42FE69D4-D6D1-4F90-BA48-03FEF805FBC4Q36331373-BE7BABF9-40FC-49D4-BBC5-2BF0242FCD57Q36481940-700070BE-D5E7-44EC-9F42-48EF8BF746BCQ36556362-010C5747-01BB-47D8-8744-33614C4A4CECQ36581657-63A34886-0EC9-4123-9E22-52036164F5DCQ36581663-1836C52F-7444-487E-85E3-70F30A897BEAQ36736351-0CE978F5-FB74-441E-AD02-B8153B72B4E3Q36736358-C20DC0C9-A6A1-468A-AE69-DF9870A5CB22Q36926098-F41CC3F9-D3A5-486E-8A78-ABCB8287CDF4Q37046414-F819711B-9675-4E62-9740-C749C3E18838Q37362747-A24EEBA3-26B1-490F-963C-201A19415502Q37420163-72419116-1D2D-45D6-B128-642F5A699A1FQ37691694-6843613A-7C7B-4CB5-A8BD-15ED165EB19AQ38129174-3F8B4B2A-61B6-4042-8FF2-9073A37BE35CQ38180665-A96BA8BB-A4BF-4209-BE07-A3C36662283EQ38186535-C29250D3-B663-4BBF-87CD-608E36F0481BQ38252591-011C3B82-2EA6-4FEF-9A63-9CB84A0914F5Q38659528-2E16FA1A-5D14-4AF9-9FE9-7BED6DF15527Q38709284-47EA9F0D-B7FF-461D-97D4-5F06B156D3DBQ38908701-D9CD3FD2-E7B8-4CAA-BE23-1E463718A7A5Q38997351-A5869640-66D2-4CED-8FA0-CF04463A6BB8
P2860
Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Mutant p53 uses p63 as a molec ...... nduce a pro-invasive secretome
@en
Mutant p53 uses p63 as a molec ...... duce a pro-invasive secretome.
@nl
type
label
Mutant p53 uses p63 as a molec ...... nduce a pro-invasive secretome
@en
Mutant p53 uses p63 as a molec ...... duce a pro-invasive secretome.
@nl
prefLabel
Mutant p53 uses p63 as a molec ...... nduce a pro-invasive secretome
@en
Mutant p53 uses p63 as a molec ...... duce a pro-invasive secretome.
@nl
P2093
P2860
P50
P356
P1433
P1476
Mutant p53 uses p63 as a molec ...... nduce a pro-invasive secretome
@en
P2093
Andreas Evdokiou
David F Callen
Rachel J Suetani
Renee B Schulz
P2860
P304
P356
10.18632/ONCOTARGET.382
P407
P577
2011-12-01T00:00:00Z